FLT3-ITD occurs in combination with NPM1 mutations in 40% of CN-AML [63], with the presence of an NPM1 mutation associated with improved prognosis compared to FLT3-ITD alone. This evidence concerns the gene FLT3 and acute myeloid leukemia.